- Home
- ACIU vs PCK Comparison
ACIU vs PCK Comparison
Compare ACIU & PCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- PCK
- Stock Information
- Founded
- ACIU 2003
- PCK 2002
- Country
- ACIU Switzerland
- PCK United States
- Employees
- ACIU N/A
- PCK N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- PCK Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- PCK Finance
- Exchange
- ACIU Nasdaq
- PCK Nasdaq
- Market Cap
- ACIU 173.7M
- PCK 172.2M
- IPO Year
- ACIU 2016
- PCK N/A
- Fundamental
- Price
- ACIU $1.69
- PCK $5.56
- Analyst Decision
- ACIU Strong Buy
- PCK
- Analyst Count
- ACIU 2
- PCK 0
- Target Price
- ACIU $10.00
- PCK N/A
- AVG Volume (30 Days)
- ACIU 137.1K
- PCK 79.7K
- Earning Date
- ACIU 04-30-2025
- PCK 01-01-0001
- Dividend Yield
- ACIU N/A
- PCK 4.58%
- EPS Growth
- ACIU N/A
- PCK N/A
- EPS
- ACIU N/A
- PCK N/A
- Revenue
- ACIU $32,014,254.00
- PCK N/A
- Revenue This Year
- ACIU N/A
- PCK N/A
- Revenue Next Year
- ACIU $676.94
- PCK N/A
- P/E Ratio
- ACIU N/A
- PCK N/A
- Revenue Growth
- ACIU 91.20
- PCK N/A
- 52 Week Low
- ACIU $1.43
- PCK $4.85
- 52 Week High
- ACIU $4.98
- PCK $6.33
- Technical
- Relative Strength Index (RSI)
- ACIU 46.75
- PCK 55.22
- Support Level
- ACIU $1.55
- PCK $5.50
- Resistance Level
- ACIU $1.79
- PCK $5.60
- Average True Range (ATR)
- ACIU 0.10
- PCK 0.06
- MACD
- ACIU 0.03
- PCK 0.03
- Stochastic Oscillator
- ACIU 66.67
- PCK 91.18
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About PCK Pimco California Municipal Income Fund II of Beneficial Interest
PIMCO CA Muni Income Fund II is a closed-ended investment company. Its investment objective is to seek to provide current income exempt from federal and California income tax. The company portfolio of investment comprises of different sector investments such as healthcare, education, property, and others.